[Viewpoint] Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits

Glucocorticoid pulse therapy is commonly prescribed by rheumatologists worldwide for a wide variety of serious and potentially life-threatening diseases. Pulse therapy also has the potential to lower the cumulative glucocorticoid burden, which has already been proven in systemic lupus erythematosus and giant cell arteritis. The standard practice in rheumatology is to administer this therapy intravenously, but current literature suggests that oral methylprednisolone is a non-inferior option for clinical outcomes and safety.